10 innovative startups move into the next round of BioUpper 4
The digital curtain of the Selection Day of BioUpper 4 has closed: the first Italian platform in the field of Life Sciences that supports the best entrepreneurial projects through paths of empowerment, acceleration, and market support. Conceived and promoted by Fondazione Cariplo and Novartis, and designed by the Cariplo Factory, BioUpper has also been involved with IBM for two years to focus on digital health: a fundamental branch of the healthcare sector.
The Jury of BioUpper, met digitally, decreed the 10 highest value projects, selected from over 117 applications collected, which will enter the preparation phase for the “go-to-market”: Aptus.AI, Dianax, Hero, Intra, Medere, Nuvap, Pain Chronicles, Sensedat, U-care and Ugo Pnp.
Some of the winning startups offer solutions that have already been made available to health authorities to deal with the current Covid-19 emergency and that will be further developed during the BioUpper program. The 10 startups will access an acceleration program and each of them will be able to take advantage of credits granted by IBM – up to a maximum of 120 thousand euros in 12 months – which can be spent on the use of the technological services included in the IBM Cloud catalog. The most deserving innovators will thus have the best skills and the most innovative technological tools based on the IBM Cloud platform (including AI, Blockchain, Security, Analytics, Devops, etc.) and will access a path of entrepreneurial empowerment, working in close contact with experts from Novartis, IBM, Cariplo Factory.
The next appointment will be in September, when the entrepreneurial support phase is over and the startups will meet again in front of the Jury, on the occasion of the Award Ceremony.